Moderna Inc MRNA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

Last | 04/16/24 EDT

103.44UNCH (UNCH)

Volume

1,830,558

52 week range

62.55 - 156.75

Open105.14
Day High105.14
Day Low102.27
Prev Close103.44
52 Week High156.75
52 Week High Date04/17/23
52 Week Low62.55
52 Week Low Date11/02/23

Key Stats

Market Cap39.605B
Shares Out382.88M
10 Day Average Volume3.50M
Dividend-
Dividend Yield-
Beta1.58
YTD % Change4.01

KEY STATS

Open105.14
Day High105.14
Day Low102.27
Prev Close103.44
52 Week High156.75
52 Week High Date04/17/23
52 Week Low62.55
52 Week Low Date11/02/23
Market Cap39.605B
Shares Out382.88M
10 Day Average Volume3.50M
Dividend-
Dividend Yield-
Beta1.58
YTD % Change4.01

RATIOS/PROFITABILITY

EPS (TTM)-12.39
P/E (TTM)-8.35
Fwd P/E (NTM)-14.14
EBITDA (TTM)-3.617B
ROE (TTM)-28.59%
Revenue (TTM)6.848B
Gross Margin (TTM)31.47%
Net Margin (TTM)-68.84%
Debt To Equity (MRQ)4.15%

EVENTS

Earnings Date05/02/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Moderna Inc

Moderna halts plans to build Kenya vaccine plant as Covid shot demand plungesApril 11, 2024CNBC.com
Stocks making the biggest moves midday: Boeing, Norfolk Southern, Nvidia & moreApril 9, 2024CNBC.com
Stocks making the biggest moves midday: GameStop, Merck, Carnival and moreMarch 27, 2024CNBC.com
Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and moreMarch 27, 2024CNBC.com
Moderna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patientsMarch 27, 2024CNBC.com

Content From Our Affiliates

Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor PushApril 15, 2024TipRanks
Biotech Alert: Searches spiking for these stocks todayApril 12, 2024TipRanks
Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in KenyaApril 11, 2024TipRanks
Moderna pauses efforts to build vaccine plant in Kenya, FT saysApril 11, 2024TipRanks
Maintaining a Hold: Assessing Moderna’s Prospects Amidst Evolving Markets and Uncertain DevelopmentsApril 11, 2024TipRanks

Profile

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the...

Noubar Afeyan Ph.D.

Non-Executive Independent Chairman of the Board, Co-Founder

Stephane Bancel

Chief Executive Officer, Director

Stephen Hoge M.D.

President

Jerh Collins

Chief Technical Operations and Quality Officer

James Mock

Chief Financial Officer

Brad Miller

Chief Information Officer

Address

325 BINNEY STREET

Cambridge, MA

02142

United States

https://www.modernatx.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
BIIB Biogen Inc	192.16	UNCH	UNCH
ILMN Illumina Inc	118.29	UNCH	UNCH
BNTX Biontech SE	86.40	UNCH	UNCH
GRFS Grifols SA	6.58	UNCH	UNCH
CRL Charles River Laboratories International Inc	230.09	UNCH	UNCH